SMSven Mahner

Sven Mahner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sven Mahner has a total of 152 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer.

    by Marie Lena Johanna Tzschaschel, Brigitte Kathrin Rack, Ulrich Andergassen, Thomas W. P. Friedl, Andreas Schneeweiss, Volkmar Müller, Tanja N. Fehm, Klaus Pantel, Jörg Gade, Ralf Lorenz, et al.

    11529 Background: The presence of circulating tumor cells (CTCs) before chemotherapy (CTX) is an independent prognostic marker for reduced survival in early breast cancer (EBC). In addition, recent results suggest that persisting CTCs immediately after adjuvant CTX indicate poor prognosis. There is a lack of data regarding the best use of CTC numbers for risk stratification. Here, we evaluated different methods to calculate changes in CTC counts during the course of CTX and their prognostic value with respect to overall survival (OS). Methods: The German SUCCESS A trial is a phase III study in which patients with high-risk EBC were first randomized to adjuvant CTX treatment with 3 cycles of epirubicin-fluorouracil-cyclophosphamide followed by either 3 cycles of docetaxel or 3 cycles of gemcitabine-docetaxel. CTC enumeration was performed using the FDA-approved CellSearch System (Janssen Diagnostics, LLC). Patient outcome in terms of OS was analyzed using univariate log-rank tests and Cox regression models. Information on CTC status before and after CTX was available for 1507 (40.1 %) of 3754 randomized patients. Results: Overall, 311 patients had at least one CTC before CTX (median 1 CTC, range 1 – 827) and were included in the analyses. 79 (25.4%) of these patients had at least one CTC after CTX (median 1, range 1 – 124). A quantitative assessment with the change in number of CTCs (before and after CTX) as continuous variable significantly predicted OS (hazard ratio [HR] 0.995, 95% confidence interval [CI] 0.992-0.998, p = 0.002). Surprisingly CTC clearance (no vs. yes) was not significantly associated with OS (HR 1.508, 95% CI 0.783- 2.904, p = 0.216). However, patients that showed an increase in CTC number from before to after CTX had significantly shorter OS than patients with no such increase (HR 3.545, 95% CI 1.490- 8.434, p = 0.004). Conclusions: Both a quantitative assessment in terms of changes in CTC numbers from before to after CTX and a qualitative measure according to whether or not there was an increase in CTC number showed a significant association with overall survival in EBC patients. Clinical trial information: NCT02181101.

  • Aktuelle Studien zum Ovarialkarzinom

    by Priv.-Doz. Dr. Med. Sven Mahner, Linn Wölber, Gunhild Von Amsberg, Felix Hilpert, Klaus Baumann, Stefan Kommoss, Nikolaus De Gregorio, Philipp Harter, Fabian Trillsch

  • Open Access

    Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study

    by Sven Mahner, Julia Jueckstock, Felix Hilpert, Petra Neuser, Philipp Harter, Nikolaus de Gregorio, Annette Hasenburg, Jalid Sehouli, Annika Habermann, Peter Hillemanns, et al.

    Women with node-positive vulvar cancer have a high risk for disease recurrence. Indication criteria for adjuvant radiotherapy are controversial. This study was designed to further understand the role of adjuvant therapy in node-positive disease. Patients with primary squamous-cell vulvar cancer treated at 29 gynecologic cancer centers in Germany from 1998 through 2008 were included in this retrospective exploratory multicenter cohort study. Of 1618 documented patients, 1249 had surgical groin staging and known lymph node status and were further analyzed. All statistical tests were two-sided. Four hundred forty-seven of 1249 patients (35.8%) had lymph node metastases (N+). The majority of N+ patients had one (172 [38.5%]) or two (102 [22.8%]) positive nodes. The three-year progression-free survival (PFS) rate of N+ patients was 35.2%, and the overall survival (OS) rate 56.2% compared with 75.2% and 90.2% in node-negative patients (N-). Two hundred forty-four (54.6%) N+ patients had adjuvant therapy, of which 183 (40.9%) had radiotherapy directed at the groins (+/-other fields). Three-year PFS and OS rates in these patients were better compared with N+ patients without adjuvant treatment (PFS: 39.6% vs 25.9%, hazard ratio [HR] = 0.67, 95% confidence interval [CI[= 0.51 to 0.88, P = .004; OS: 57.7% vs 51.4%, HR = 0.79, 95% CI = 0.56 to 1.11, P = .17). This effect was statistically significant in multivariable analysis adjusted for age, Eastern Cooperative Oncology Group, Union internationale contre le cancer stage, grade, invasion depth, and number of positive nodes (PFS: HR = 0.58, 95% CI = 0.43 to 0.78, P < .001; OS: HR = 0.63, 95% CI = 0.43 to 0.91, P = .01). This large multicenter study in vulvar cancer observed that adjuvant radiotherapy was associated with improved prognosis in node-positive patients and will hopefully help to overcome concerns regarding adjuvant treatment. However, outcome after adjuvant radiotherapy remains poor compared with node-negative patients. Adjuvant chemoradiation could be a possible strategy to improve therapy because it is superior to radiotherapy alone in other squamous cell carcinomas.


  • Open Access

    Surgery or topical therapy for vulval intraepithelial neoplasia

    by Sven Mahner, Linn Wölber


  • Innovationen in der medikamentösen Therapie des Ovarialkarzinoms

    by S. Mahner, L. Wölber, F. Hilpert, K. Baumann, S. Kommoss, N. de Gregorio, P. Harter, F. Trillsch

  • Open Access

    Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study

    by F. Trillsch, S. Mahner, L. Woelber, E. Vettorazzi, A. Reuss, N. Ewald-Riegler, N. de Gregorio, C. Fotopoulou, B. Schmalfeldt, A. Burges, et al.

    Approximately one-third of all borderline ovarian tumours (BOT) are diagnosed in patients with child-bearing potential. Detailed information regarding their specific characteristics and prognostic factors is limited. Clinical parameters of BOT patients treated between 1998 and 2008 in 24 German centres were retrospectively investigated. Central pathology review and prospective follow-up were carried out. Patients P < 0.001), usually in ovarian tissue, whereas disease-specific overall survival did not differ between the subgroups. In case of recurrent disease, malignant transformation was less frequent in younger than in older patients (12.0% versus 66.7%, P < 0.001), mostly presenting as invasive peritoneal carcinomatosis. Multivariate analysis for patients <40 years identified advanced International Federation of Gynecology and Obstetrics (FIGO) stage and fertility-sparing approach as independent prognostic factors negatively affecting progression-free survival (PFS) while, for patients ≥40 years, higher FIGO stage and incomplete staging was associated with impaired PFS. Despite favourable survival, young BOT patients with child-bearing potential are at higher risk for disease recurrence. However, relapses usually remain BOT in the preserved ovaries as opposed to older patients being at higher risk for malignant transformation in peritoneal or distant localisation. Therefore, fertility-sparing approach can be justified for younger patients after thorough consultation.


  • The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns

    by Ivana Türbachova, Tim Schwachula, Ines Vasconcelos, Alexander Mustea, Tina Baldinger, Katherine A Jones, Hermann Bujard, Alexander Olek, Klaus Olek, Katharina Gellhaus, et al.

    The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the “cellular ratio of immune tolerance” (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.


  • Rezidivtherapie des Ovarialkarzinoms

    by S. Mahner, L. Woelber, P. Harter, F. Hilpert, U. Wagner, F. Jaenicke, F. Trillsch

  • Open Access

    Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT)

    by Fabian Trillsch, Jan David Ruetzel, Uwe Herwig, Ulrike Doerste, Linn Woelber, Donata Grimm, Matthias Choschzick, Fritz Jaenicke, Sven Mahner

    Background: Surgery is the cornerstone for clinical management of patients with borderline ovarian tumors (BOT). As these patients have an excellent overall prognosis, perioperative morbidity is the critical point for decision making when the treatment strategy is developed and the primary surgical approach is defined. Methods: Clinical and surgical parameters of patients undergoing surgery for primary BOT at our institutions between 1993 and 2008 were analyzed with regard to perioperative morbidity depending on the surgical approach (laparotomy vs. laparoscopy). Results: A total of 105 patients were analyzed (44 with primary laparoscopy [42%], 61 with primary laparotomy [58%]). Complete surgical staging was achieved in 33 patients at primary surgical approach (31.4%) frequently leading to formal indication of re-staging procedures. Tumor rupture was significantly more frequent during laparoscopy compared to laparotomy (29.5% vs. 13.1%, p = 0.038) but no other intraoperative complications were seen in laparoscopic surgery in contrast to 7 of 61 laparotomies (0% vs. 11.5%, p = 0.020). Postoperative complication rates were similar in both groups (19.7% vs. 18.2%, p = 0.848). Conclusions: Irrespective of the surgical approach, surgical management of BOT has acceptable rates of perioperative complications and morbidity. Choice of initial surgical approach can therefore be made independent of complication-concerns. As the recently published large retrospective AGO ROBOT study observed similar oncologic outcome for both approaches, laparoscopy can be considered for staging of patients with BOT if this appears feasible. An algorithm for the surgical management of BOT patients has been developed.